This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Review

. 1970 Apr 4;226(5240):21-4.

doi: 10.1038/226021a0.

L-Dopa and Parkinsonism

D B Calne, M Sandler

PMID: 4907560
DOI: 10.1038/226021a0

Review

L-Dopa and Parkinsonism

D B Calne et al. Nature. 1970.

. 1970 Apr 4;226(5240):21-4.

doi: 10.1038/226021a0.

Authors

D B Calne, M Sandler

PMID: 4907560
DOI: 10.1038/226021a0

No abstract available

PubMed Disclaimer

Similar articles

L-Dopa in the treatment of parkinsonism.
Calne DB. Calne DB. Clin Pharmacol Ther. 1970 Nov-Dec;11(6):789-801. doi: 10.1002/cpt1970116789. Clin Pharmacol Ther. 1970. PMID: 4921292 Review. No abstract available.
The pharmacology of parkinsonism (a review).
Klawans HL Jr. Klawans HL Jr. Dis Nerv Syst. 1968 Dec;29(12):805-16. Dis Nerv Syst. 1968. PMID: 4388368 Review. No abstract available.
[Treatment of Parkinson's disease with L-dopa].
Guglielmi L, Vecchi L. Guglielmi L, et al. Clin Ter. 1970 May 15;53(3):259-69. Clin Ter. 1970. PMID: 4917328 Review. Italian. No abstract available.
Theoretical implications of the use of L-dopa in parkinsonism. A review.
Klawans H Jr, Ilahi MM, Shenker D. Klawans H Jr, et al. Acta Neurol Scand. 1970;46(4):409-41. doi: 10.1111/j.1600-0404.1970.tb05804.x. Acta Neurol Scand. 1970. PMID: 4323341 Review. No abstract available.
How does L-dopa work in parkinsonism?
Sandler M. Sandler M. Lancet. 1971 Apr 17;1(7703):784. doi: 10.1016/s0140-6736(71)91219-0. Lancet. 1971. PMID: 4101278 No abstract available.

See all similar articles

Cited by

In vivo assessment of decarboxylase inhibition or potentiation: urinary dopamine and L-dopa output after L-dopa administration.
Johnson RD, Ruthven CR, Goodwin BL, Sandler M. Johnson RD, et al. J Neural Transm. 1976;38(3-4):181-91. doi: 10.1007/BF01249438. J Neural Transm. 1976. PMID: 956809
Targeting serum response factor (SRF) deactivates ΔFosB and mitigates Levodopa-induced dyskinesia in a mouse model of Parkinson's disease.
Kambey PA, Wu J, Liu W, Su M, Buberwa W, Tang C. Kambey PA, et al. Gene Ther. 2024 Nov;31(11-12):614-624. doi: 10.1038/s41434-024-00492-8. Epub 2024 Oct 9. Gene Ther. 2024. PMID: 39384937
Environment and Gene Association With Obesity and Their Impact on Neurodegenerative and Neurodevelopmental Diseases.
Flores-Dorantes MT, Díaz-López YE, Gutiérrez-Aguilar R. Flores-Dorantes MT, et al. Front Neurosci. 2020 Aug 28;14:863. doi: 10.3389/fnins.2020.00863. eCollection 2020. Front Neurosci. 2020. PMID: 32982666 Free PMC article. Review.
Pyridoxal 5'-phosphate levels in brain after treatments which impair cerebral glucose metabolism.
Wong KL, Tyce GM. Wong KL, et al. Neurochem Res. 1979 Dec;4(6):821-6. doi: 10.1007/BF00964478. Neurochem Res. 1979. PMID: 44547
Study of autocorrelations and uncertainties applied to patients with Parkinson's disease.
Oliveira Filho FM, Dos Santos Silva EF, de Freitas Santos SE, Bandeira Santos AÁ, Zebende GF. Oliveira Filho FM, et al. Sci Rep. 2025 Mar 24;15(1):10068. doi: 10.1038/s41598-025-94252-2. Sci Rep. 2025. PMID: 40128547 Free PMC article.

See all "Cited by" articles

Publication types

Actions
Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
- Nature Publishing Group
Other Literature Sources
- The Lens - Patent Citations Database